BioCentury | Mar 9, 2018
Clinical News

Cynata reports Phase I data for mesenchymal stem cell GvHD product

...graft-versus-host disease (GvHD) in the first cohort of the Phase I CYP-GvHD-P1-01 trial showing that CYP-001...
...HSCT) for a hematological disorder. Patients in the first cohort received 1 million cells/kg IV CYP-001...
...Cynata. CYP-001 is manufactured using Cynata’s Cymerus platform which originated from the University of Wisconsin-Madison. CYP-001...
BioCentury | Jul 20, 2017
Product R&D

Inducing competition for MSCs

...technology for creating MSCs from iPS cells met the necessary CMC expectations, indicating its lead CYP-001...
...the U.S. According to CEO Ross MacDonald, the company plans to submit an IND on CYP-001...
...MI) and stroke. Source: ClinicalTrials.gov Table: BioCentury Product Profile BIOCENTURY PRODUCT PROFILE INNOVATION STAGE Product CYP-001...
BioCentury | May 19, 2017
Clinical News

Cynata starts Phase I of mesenchymal stem cells to treat GvHD

...Cynata Therapeutics Ltd. (ASX:CYP) began a Phase I trial to evaluate CYP-001 in about 16 patients...
...transplant for a hematological disorder. Patients will receive 1 million or 2 million cells/kg IV CYP-001...
...Wis.). CYP-001 comprises mesenchymoangioblast-derived mesenchymal stem cells (MSC). Cynata Therapeutics Ltd. (ASX:CYP), Armadale, Australia Product: CYP-001...
Items per page:
1 - 3 of 3